Skip to content
Other

Less than 12 months

Moderna Less than 12 months increased by 800.0% to $9M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 350.0%, from $2M to $9M. Over 4 years (FY 2021 to FY 2025), Less than 12 months shows a downward trend with a -62.8% CAGR.

Analysis

StatementBalance Sheet Statement
SectionOther
First reportedQ4 2019
Last reportedQ1 2026May 1, 2026
Metric ID: other_debt_securities_available_for_sale_continuous_unre_4cdf47

Historical Data

18 periods
 Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Value$52M$271M$357M$373M$241M$59M$46M$14M$4M$11M$9M$1M$6M$2M$2M$0$1M$9M
QoQ Change+421.2%+31.7%+4.5%-35.4%-75.5%-22.0%-69.6%-71.4%+175.0%-18.2%-88.9%+500.0%-66.7%+0.0%-100.0%+800.0%
YoY Change+363.5%-78.2%-87.1%-96.2%-98.3%-81.4%-80.4%-92.9%+50.0%-81.8%-77.8%-100.0%-83.3%+350.0%
Range$0$373M
CAGR-33.8%
Avg YoY Growth-13.9%
Median YoY Growth-81.6%

Less than 12 months at Other Companies

Frequently Asked Questions

What is Moderna's less than 12 months?
Moderna (MRNA) reported less than 12 months of $9M in Q1 2026.
How has Moderna's less than 12 months changed year-over-year?
Moderna's less than 12 months increased by 350.0% year-over-year, from $2M to $9M.
What is the long-term trend for Moderna's less than 12 months?
Over 4 years (2021 to 2025), Moderna's less than 12 months has grown at a -62.8% compound annual growth rate (CAGR), from $52M to $1M.